ATE549352T1 - Verwendung sekretierter proteinprodukte zur prävention und behandlung von erkrankungen der bauchspeicheldrüse und/oder adipositas und/oder des metabolischen syndroms - Google Patents

Verwendung sekretierter proteinprodukte zur prävention und behandlung von erkrankungen der bauchspeicheldrüse und/oder adipositas und/oder des metabolischen syndroms

Info

Publication number
ATE549352T1
ATE549352T1 AT09163270T AT09163270T ATE549352T1 AT E549352 T1 ATE549352 T1 AT E549352T1 AT 09163270 T AT09163270 T AT 09163270T AT 09163270 T AT09163270 T AT 09163270T AT E549352 T1 ATE549352 T1 AT E549352T1
Authority
AT
Austria
Prior art keywords
obesity
prevention
treatment
metabolic syndrome
secreted protein
Prior art date
Application number
AT09163270T
Other languages
English (en)
Inventor
Daria Onichtchouk
Original Assignee
Develogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen Ag filed Critical Develogen Ag
Application granted granted Critical
Publication of ATE549352T1 publication Critical patent/ATE549352T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT09163270T 2004-02-20 2005-02-18 Verwendung sekretierter proteinprodukte zur prävention und behandlung von erkrankungen der bauchspeicheldrüse und/oder adipositas und/oder des metabolischen syndroms ATE549352T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04003914 2004-02-20

Publications (1)

Publication Number Publication Date
ATE549352T1 true ATE549352T1 (de) 2012-03-15

Family

ID=34878165

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09163270T ATE549352T1 (de) 2004-02-20 2005-02-18 Verwendung sekretierter proteinprodukte zur prävention und behandlung von erkrankungen der bauchspeicheldrüse und/oder adipositas und/oder des metabolischen syndroms

Country Status (6)

Country Link
US (2) US20070248579A1 (de)
EP (2) EP2096120B1 (de)
AT (1) ATE549352T1 (de)
DK (1) DK2096120T3 (de)
ES (1) ES2384134T3 (de)
WO (1) WO2005079840A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092214A1 (en) * 2007-02-02 2008-08-07 Minomic International Limited Biomarkers for diabetes
US9446096B2 (en) 2011-12-30 2016-09-20 Joslin Diabetes Center, Inc. Glypican-4 based compositions and methods for treating and diagnosing insulin resistance
CN103113468B (zh) * 2013-01-17 2014-05-21 中国人民解放军军事医学科学院基础医学研究所 一种抗肿瘤蛋白质
KR102065150B1 (ko) 2018-04-27 2020-01-10 (주)케어젠 이소트레티노인-펩타이드 결합체를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물
IL288024B2 (en) 2019-05-14 2025-12-01 Provention Bio Inc Methods and compositions for preventing type
EP4114428A4 (de) 2020-03-05 2025-03-12 Diamedica USA Inc. Ulinastatinpolypeptide
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
AU2022283271A1 (en) 2021-05-24 2023-12-07 Provention Bio, Inc. Methods for treating type 1 diabetes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US5474796A (en) 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
US5605662A (en) 1993-11-01 1997-02-25 Nanogen, Inc. Active programmable electronic devices for molecular biological analysis and diagnostics
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5886029A (en) * 1997-09-05 1999-03-23 Dhaliwal; Kirpal S. Method and composition for treatment of diabetes
WO2001000672A1 (en) * 1999-06-29 2001-01-04 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US20030170781A1 (en) * 1999-07-01 2003-09-11 Zymogenetics, Inc. Secreted protein zacrp4
JP2005508601A (ja) * 2000-12-19 2005-04-07 キュラジェン コーポレイション ポリペプチドおよびそれをコードする核酸
US20040248156A1 (en) * 2001-12-03 2004-12-09 Tianhua Hu Methods and materials relating to novel C1q domain-containing polypeptides and polynucleotides
AU2003219167A1 (en) * 2002-03-19 2003-09-29 Genset Sa Treatment of metabolic disorders with a tnf receptor family member (fradj and/or cryptic) agonists or antagonists

Also Published As

Publication number Publication date
EP2096120A3 (de) 2009-12-02
WO2005079840A3 (en) 2006-10-26
WO2005079840A2 (en) 2005-09-01
ES2384134T3 (es) 2012-06-29
EP2096120A2 (de) 2009-09-02
DK2096120T3 (da) 2012-07-09
US20090298771A1 (en) 2009-12-03
EP2096120B1 (de) 2012-03-14
EP1730189A2 (de) 2006-12-13
US20070248579A1 (en) 2007-10-25

Similar Documents

Publication Publication Date Title
ATE374766T1 (de) 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
EP1758597A4 (de) Verwendung von arzneimittelkombinationen zur behandlung der insulinresistenz
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
EA200900623A1 (ru) Бициклические соединения и их применение в качестве противодиабетических средств
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
ATE432693T1 (de) Kombinationstherapie zur behandlung von diabetes und dadurch bedingten leiden sowie zur behandlung von mittels erhöhung des glp-1-spiegels im blut verbesserten leiden
ATE367161T1 (de) (3-oxo-3,4-dihydro-chinoxalin-2-yl-amino)- benzamid-derivate und verwandte verbindungen als glykogen-phosphorylase-hemmer zur behandlung von diabetes und adipositas
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
DE602006002982D1 (de) Verwendung von 3,11b-cis-dihydrotetrabenazin zur behandlung von symptomen der huntington-krankheit
ATE438623T1 (de) Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
ATE549352T1 (de) Verwendung sekretierter proteinprodukte zur prävention und behandlung von erkrankungen der bauchspeicheldrüse und/oder adipositas und/oder des metabolischen syndroms
ATE397453T1 (de) Zusammensetzung zur behandlung und/oder vorbeugung von insulinresistenz
DE602005013788D1 (de) ckrox-Peptide und ihre Analoge zur Behandlung von Hautalterung
EA200501711A1 (ru) Семейство секретируемых белков
DE502006008804D1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
ATE495271T1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
ATE466959T1 (de) Verfahren zur vorhersage des ansprechens von patienten mit multipler sklerose auf eine interferontherapie und zur diagnose von multipler sklerose
EP1734827A4 (de) Verfahren und zusammensetzungen zur behandlung von mit anomaler mikrosatellitenexpansion in verbindung stehenden krankheiten
ATE486612T1 (de) Verfahren zur behandlung von diabetes typ 2
WO2006046073A3 (en) C1q related protein
WO2005053728A3 (de) Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik
WO2007139970A3 (en) Men1 gene for diagnosis and treatment of diabetes
DE602006010737D1 (de) 3-(4-äÄ4-(4äÄ3-(3,3-DIMETHYL-1-PIPERIDINYL)PROPYLÄOXYÜPHINYLÜ-1-PIPERIDINYLCARBONYLü-1-NAPHTHALINYL)PROPAN- ODER PROPENSÄURE ALS H1- UND H3-REZEPTOR-ANTAGONISTEN ZUR BEHANDLUNG ENTZÜNDLICHER UND/ODER ALLERGISCHER ERKRANKUNGEN
WO2005005471A3 (en) Use of dg153 secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome